Brought to you by 
Adnexus uses PROfusion to give BMS cancer candidates
15 May 2007
Executive Summary
Protein medicines developer Adnexus Therapeutics has agreed to use its PROfusion system to discover preclinical Adnectin drug candidates against up to six cancer targets for Bristol-Myers Squibb.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adnexus uses PROfusion to give BMS cancer candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice